Abstract
Hypertrophic cardiomyopathy has become a highly manageable condition due to recent therapeutic advances that have significantly reduced its overall mortality rate. However, sudden cardiac death continues to be a critical and unsolved threat, particularly in younger patients and competitive athletes. Even after recent updates to guidelines on sudden cardiac death risk evaluation in hypertrophic cardiomyopathy, new clinical evidence continues to emerge, further enriching our understanding of risk stratification and management. In this review, we summarize current research findings and explore recent advances to provide insights into future directions in the treatment of hypertrophic cardiomyopathy.